Liminal BioSciences (LMNL) Reports Q3 Revenues of $600K
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Liminal BioSciences Reports Third Quarter Financial Results
November 12, 2020 4:57 PM ESTPDUFA Target Action Date of June 5, 2021 for Ryplazim® (plasminogen) BLA Submission Ryplazim® (plasminogen) Abstracts Selected for Presentation at American Society of Hematology (ASH) in early December Changes to Board of Directors OXER1 Antagonist Preclinical R&D Program Acquired New Appointments to Board of Directors US$30 MM in gross proceeds from a private placement closed in November C$29.1 MM in proceeds from long-term loan from SALP in September Executive team changes
LAVAL, QC, and CAMBRIDGE, England, Nov. 12, 2020 /PRNewswire/ -... More
